North America Oncology Biomarkers Market Size, Share, and Growth Forecast 2026 - 2033

The North America oncology biomarkers market size is expected to be valued at US$ 11.9 billion in 2026 and projected to reach US$ 21.1 billion by 2033, growing at a CAGR of 8.6% between 2026 and 2033.

Growing precision oncology adoption across the region is the primary force propelling this expansion, as clinicians increasingly rely on molecular testing to guide individualized treatment decisions. This momentum is reinforced by the American Cancer Society estimate of over 2 million new cancer cases diagnosed in the U.S. in 2024, expanding companion diagnostic clearances issued by the U.S. Food and Drug Administration (FDA), and rising National Institutes of Health (NIH) funding directed toward genomic and translational cancer research programs.

Drivers - Rising Cancer Incidence Accelerating Demand for Molecular Diagnostics

Cancer remains one of the leading causes of mortality across North America, and this rising disease burden is a fundamental driver for biomarker adoption. According to the American Cancer Society 2.0 million new cancer cases were projected for the U.S. in 2024, while the Canadian Cancer Society estimates nearly 247,100 new cancer diagnoses annually in Canada. This escalating incidence has intensified the need for accurate, early-stage detection tools that support timely intervention and personalized therapy selection. Government-backed screening initiatives, including programs supported by the Centers for Disease Control and Prevention (CDC), are further reinforcing biomarker-based diagnostic uptake, as clinicians increasingly integrate molecular profiling into routine oncology workflows to improve patient outcomes and reduce late-stage diagnoses.

Expanding Companion Diagnostics and Precision Medicine Adoption

The shift toward precision medicine is significantly strengthening biomarker demand, as targeted therapies increasingly require companion diagnostic confirmation before administration. The U.S. Food and Drug Administration (FDA) has approved a growing list of companion diagnostic devices linked to targeted oncology drugs, particularly for lung, breast, and colorectal cancers, compelling laboratories to adopt validated biomarker assays. Additionally, the National Cancer Institute (NCI) continues to expand its Precision Medicine Initiative, funding trials such as NCI-MATCH that match patients to therapies based on tumor genetic alterations. This regulatory and research momentum is encouraging diagnostic manufacturers to accelerate assay development, reinforcing the market's transition from generalized chemotherapy toward biomarker-guided, individualized cancer treatment protocols across the region.

Restraints - High Cost of Advanced Genomic Testing Limiting Broader Access

Comprehensive genomic profiling and next-generation sequencing panels often carry substantial per-test costs, ranging from several hundred to a few thousand dollars, creating affordability barriers for uninsured and underinsured patient populations. Reimbursement inconsistencies across private insurers and the Centers for Medicare & Medicaid Services (CMS) coverage determinations further complicate patient access, particularly for newer multi-gene panels that lack long-established coverage precedents. Smaller diagnostic laboratories also face capital constraints in acquiring high-throughput sequencing infrastructure, slowing adoption in community and rural healthcare settings compared with large academic medical centers with established molecular pathology departments.

Complex Regulatory and Validation Requirements for Novel Assays

Bringing a new oncology biomarker assay to market requires extensive analytical and clinical validation to satisfy U.S. Food and Drug Administration (FDA) premarket requirements, a process that can extend development timelines by several years. Laboratory-developed tests must additionally comply with Clinical Laboratory Improvement Amendments (CLIA) standards, adding further procedural complexity. These stringent pathways increase development costs for diagnostic companies and can delay commercialization of promising biomarker panels, particularly for smaller innovators lacking dedicated regulatory affairs teams, thereby moderating the pace at which novel biomarker technologies reach clinical practice.

Opportunities - Rising Potential of Liquid Biopsy and Minimal Residual Disease Monitoring

Liquid biopsy technology is emerging as a transformative opportunity for market participants, offering a minimally invasive alternative to tissue biopsies for detecting circulating tumor DNA and monitoring treatment response. Companies such as Guardant Health, Inc. and Exact Sciences Corporation have expanded their blood-based testing portfolios to support minimal residual disease detection and early recurrence monitoring across colorectal and lung cancers. The U.S. Food and Drug Administration (FDA) has granted breakthrough device designations to several liquid biopsy assays, signaling regulatory support for accelerated development pathways. As oncologists increasingly seek longitudinal, non-invasive monitoring solutions to track therapy efficacy and detect relapse earlier, diagnostic developers investing in liquid biopsy platforms stand to capture substantial incremental demand across both academic and community oncology settings.

Growing Integration of Epigenetic Biomarkers and Next-Generation Sequencing

Epigenetic biomarkers, including DNA methylation signatures, are gaining traction as a high-growth opportunity area, given their ability to detect cancer at earlier stages than many genetic mutations alone. Research supported by the National Institutes of Health (NIH) continues to validate methylation-based assays for colorectal and multi-cancer early detection applications, expanding their clinical relevance. Simultaneously, Illumina, Inc. and Thermo Fisher Scientific Inc. are broadening next-generation sequencing platform capabilities to capture epigenetic alterations alongside genomic variants within a single workflow, improving diagnostic efficiency. As multi-cancer early detection tests move through clinical validation studies, diagnostic and pharmaceutical companies that integrate epigenetic biomarker discovery into their pipelines are well positioned to address unmet needs in early-stage oncology screening across North America.

Biomarker Type Analysis

Genetic/Genomic Biomarkers led the North America oncology biomarkers market, accounting for a 45% share in 2026, supported by widespread clinical reliance on mutation-based testing for genes such as EGFR, KRAS, and BRCA1/2. The segment's dominance is reinforced by the National Cancer Institute's continued emphasis on genomic characterization through initiatives like The Cancer Genome Atlas (TCGA), which has generated extensive reference datasets used in clinical assay development. Genetic biomarkers remain central to companion diagnostic requirements mandated ahead of targeted therapy administration, particularly in lung, breast, and colorectal cancers. Meanwhile, Epigenetic Biomarkers are emerging as the fastest-growing category, driven by expanding research into DNA methylation patterns for early cancer detection and their integration into next-generation multi-cancer screening panels.

Cancer Type Analysis

Lung Cancer represented the leading cancer type segment, capturing an estimated 27% share of the North America oncology biomarkers market in 2026, attributable to the high prevalence of actionable mutations such as EGFR, ALK, and PD-L1 that guide targeted therapy and immunotherapy selection. According to the American Lung Association, lung cancer remains a leading cause of cancer mortality in the U.S., reinforcing consistent biomarker testing demand across diagnostic and treatment-monitoring settings. Clinical guidelines from the National Comprehensive Cancer Network (NCCN) recommend routine biomarker testing prior to first-line therapy initiation for non-small cell lung cancer patients. Melanoma is registering the fastest growth, propelled by expanding BRAF and PD-L1 biomarker testing supporting immune checkpoint inhibitor therapies.

North America Oncology Biomarkers Market Trends and Insights

North America remains a leading region in the global oncology biomarkers market, supported by advanced healthcare infrastructure, strong research capabilities, and widespread adoption of precision oncology. The region benefits from substantial research funding through the National Institutes of Health (NIH) and the presence of major diagnostic and biotechnology companies. Increasing use of genomic profiling, companion diagnostics, circulating tumor DNA (ctDNA), and liquid biopsy technologies is strengthening biomarker adoption across clinical and research settings. Favorable reimbursement policies, expanding oncology clinical trials, and growing demand for personalized cancer treatment are further supporting market growth throughout the region.

U.S. Oncology Biomarkers Market Size

The U.S. dominated the North American oncology biomarkers market, accounting for 88% of the regional market in 2026. Market leadership is supported by extensive adoption of precision medicine, a high volume of cancer diagnoses, and increasing use of molecular testing for treatment selection. The U.S. Food and Drug Administration (FDA) has approved numerous companion diagnostics linked to targeted cancer therapies, strengthening the clinical integration of biomarkers. In addition, strong healthcare expenditure, advanced laboratory infrastructure, comprehensive insurance coverage, and the presence of leading diagnostic and biotechnology companies continue to drive demand for genomic, molecular, and liquid biopsy-based oncology testing.

Canada Oncology Biomarkers Market Size

Canada represents a growing market for oncology biomarkers, supported by increasing investment in cancer genomics, precision medicine, and molecular diagnostic infrastructure. Provincial healthcare systems are progressively incorporating biomarker testing into oncology treatment pathways, particularly for cancers where targeted therapies require molecular characterization. Rising cancer incidence and greater awareness of personalized treatment are encouraging demand for genomic profiling and companion diagnostics. Government initiatives and research funding are also supporting the development of cancer genomics capabilities across major provinces. Increasing availability of advanced molecular testing, expanding clinical research activities, and efforts to improve early cancer detection are expected to sustain the adoption of oncology biomarkers in Canada.

The North America oncology biomarkers market exhibits a moderately consolidated structure, with a handful of established diagnostic and life sciences companies holding significant technological and distribution advantages, alongside emerging specialized liquid biopsy innovators. Leading players are prioritizing strategic collaborations, companion diagnostic partnerships with pharmaceutical developers, and continuous platform innovation to strengthen their competitive positioning. Research and development investment remains heavily focused on expanding multi-gene panel capabilities, improving assay turnaround times, and enhancing sequencing accuracy. Key differentiators include breadth of test menus, regulatory clearances, and integration with electronic health record systems. Emerging business models increasingly emphasize subscription-based laboratory services and direct-to-oncologist digital reporting platforms to streamline clinical decision-making.

Key Developments

• May 2026: Roche launched its comprehensive Liver Disease Panel, introducing what the company described as the first comprehensive library of certified healthcare algorithms designed to support chronic liver disease (CLD) management. The panel combined biomarker-based diagnostics with digital algorithms to help clinicians identify liver fibrosis earlier, assess disease severity, and support surveillance for liver cancer.
• March 2026: Illumina and Labcorp expanded their collaboration in March 2026 to broaden access to precision oncology testing and accelerate the development of next-generation sequencing (NGS)-based solutions. The expanded partnership focused on bringing cancer biomarker testing closer to patients through distributed testing offerings, generating clinical evidence to support payer coverage, and developing new tests addressing unmet needs in precision oncology.